Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SPY072
SPY002-072 · 2 trials · 9 indications
HiSCR75 is defined as at least a 75% reduction from baseline in total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining tunnel count
The score is calculated based on the number of tender and swollen joints out of 28 assessed (TJC28 and SJC28), a measure of inflammation in the blood (c-reactive protein, CRP), and the subject's overall assessment of their health (patient global assessment). Scores range from 0-10. Higher scores indicate greater disease activity.
The score combines 5 disease activity variables (back pain, duration of morning stiffness, patient global assessment of disease activity, peripheral pain/swelling and measure of inflammation) to measure disease activity. Lowest score is 0.6 and increases as disease worsens. Higher scores indicate greater disease activity.
The proportion of subjects who achieve at least 20% improvement in tender and swollen joint counts (TJC and SJC), and at least 20% improvement in 3 out of 5 other disease activity measures (patient global assessment, physician global assessment, patient pain assessment, health assessment questionnaire, and measure of inflammation) will be assessed.
| Arm | Type | Description |
|---|---|---|
| SPY072 + bimekizumab | EXPERIMENTAL | Participants receive SPY072 + bimekizumab |
| Placebo + bimekizumab | PLACEBO_COMPARATOR | Participants receive matching placebo for SPY072 + bimekizumab |
| Rheumatoid Arthritis, Dose Regimen 1 | EXPERIMENTAL | Participants will receive double-blind dosing regimen 1 of SPY072 |
| Rheumatoid Arthritis, Dose Regimen 2 | EXPERIMENTAL | Participants will receive double-blind dosing regimen 2 of SPY072 |
| Psoriatic Arthritis | EXPERIMENTAL | Participants will receive double-blind dose of SPY072 |
| Axial Spondyloarthritis | EXPERIMENTAL | Participants will receive double-blind dose of SPY072 |
| Rhematoid Arthritis Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo |
| Psoriatic Arthritis Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo |
| Axial Spondyloarthritis Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo |
| Name | Type | Description |
|---|---|---|
| SPY072 | DRUG | Solution for SC injection |
| Placebo | DRUG | Matching placebo for SC injection |
| bimekizumab | DRUG | Advanced standard of care |
| SPY002-072 | DRUG | Experimental |
Inclusion Criteria: * Clinical diagnosis of Hidradenitis Suppurativa with symptoms for at least 6 months before screening. * Hidradenitis suppurativa lesions in at least 2 distinct anatomical areas, with at least 1 area meeting Hurley Stage II or III criteria at screening and Day 1. * Total abscess...
Top 20 of 31 competitors
SPY002-072 is an investigational small molecule being developed for rheumatoid arthritis and other rheumatic diseases, including psoriatic arthritis and axial spondyloarthritis. It is in Phase 2 clinical development and has not been approved for any indication.
SPY002-072 targets TL1A, a protein that plays a role in inflammatory signaling. By targeting TL1A, the drug aims to reduce inflammation associated with rheumatoid arthritis and related rheumatic conditions.
SPY002-072 is being developed by Spyre Therapeutics, Inc., which trades under the ticker SYRE. The company is advancing the drug as part of its immunology pipeline.
SPY002-072 is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 2 trial is evaluating its potential in rheumatoid arthritis and other rheumatic diseases.
SPY002-072 is being studied in a Phase 2 trial, NCT07148414, titled "A Study of SPY072 in Rheumatic Disease." The trial is active but not recruiting, with an enrollment of 285 participants across multiple countries including the United States, Bulgaria, Czechia, Georgia, Moldova, Poland, Spain, and Ukraine.